Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 25 | 2017 | 887 | 2.290 |
Why?
|
| Graft Rejection | 6 | 2015 | 566 | 0.840 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2015 | 213 | 0.520 |
Why?
|
| Extracorporeal Membrane Oxygenation | 7 | 2016 | 648 | 0.490 |
Why?
|
| Heart Failure | 8 | 2017 | 2428 | 0.410 |
Why?
|
| Heart-Assist Devices | 9 | 2016 | 1098 | 0.410 |
Why?
|
| Azygos Vein | 2 | 2013 | 8 | 0.390 |
Why?
|
| Down Syndrome | 1 | 2015 | 232 | 0.380 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 572 | 0.310 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 343 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1358 | 0.280 |
Why?
|
| Peptide Fragments | 1 | 2012 | 828 | 0.280 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2007 | 19 | 0.280 |
Why?
|
| Bone Density | 1 | 2009 | 377 | 0.260 |
Why?
|
| Child, Preschool | 22 | 2017 | 14878 | 0.260 |
Why?
|
| HLA Antigens | 3 | 2013 | 220 | 0.240 |
Why?
|
| Tissue Donors | 2 | 2012 | 507 | 0.240 |
Why?
|
| Child | 28 | 2020 | 25882 | 0.240 |
Why?
|
| Infant | 21 | 2017 | 13246 | 0.230 |
Why?
|
| Heart Defects, Congenital | 4 | 2017 | 1887 | 0.230 |
Why?
|
| Renal Insufficiency | 1 | 2007 | 256 | 0.220 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2004 | 127 | 0.200 |
Why?
|
| Isoantibodies | 2 | 2013 | 59 | 0.200 |
Why?
|
| Retrospective Studies | 18 | 2017 | 17577 | 0.180 |
Why?
|
| Stents | 1 | 2007 | 881 | 0.180 |
Why?
|
| Tissue and Organ Procurement | 1 | 2004 | 248 | 0.170 |
Why?
|
| Hospice Care | 1 | 2020 | 32 | 0.160 |
Why?
|
| Home Care Services | 1 | 2020 | 81 | 0.160 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2007 | 793 | 0.160 |
Why?
|
| Terminal Care | 1 | 2020 | 121 | 0.150 |
Why?
|
| Arkansas | 5 | 2012 | 58 | 0.150 |
Why?
|
| Female | 23 | 2017 | 71840 | 0.140 |
Why?
|
| Humans | 32 | 2020 | 133811 | 0.140 |
Why?
|
| Male | 23 | 2017 | 65939 | 0.130 |
Why?
|
| Alkaline Phosphatase | 1 | 2017 | 103 | 0.130 |
Why?
|
| Heart Diseases | 3 | 2012 | 519 | 0.130 |
Why?
|
| Adolescent | 16 | 2016 | 20610 | 0.130 |
Why?
|
| Infant, Newborn | 7 | 2016 | 8632 | 0.130 |
Why?
|
| Waiting Lists | 2 | 2016 | 241 | 0.120 |
Why?
|
| Odds Ratio | 3 | 2012 | 1323 | 0.110 |
Why?
|
| Respiration, Artificial | 2 | 2015 | 500 | 0.110 |
Why?
|
| Postoperative Hemorrhage | 1 | 2014 | 84 | 0.100 |
Why?
|
| Age of Onset | 1 | 2015 | 637 | 0.100 |
Why?
|
| Risk Factors | 7 | 2016 | 11166 | 0.100 |
Why?
|
| Vena Cava, Inferior | 1 | 2013 | 103 | 0.100 |
Why?
|
| Parvovirus B19, Human | 1 | 2012 | 31 | 0.100 |
Why?
|
| Parvoviridae Infections | 1 | 2012 | 37 | 0.100 |
Why?
|
| Dexmedetomidine | 1 | 2012 | 50 | 0.090 |
Why?
|
| Proteasome Inhibitors | 1 | 2012 | 66 | 0.090 |
Why?
|
| Ventricular Function | 1 | 2012 | 91 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2012 | 48 | 0.090 |
Why?
|
| Time Factors | 7 | 2015 | 6554 | 0.090 |
Why?
|
| Pyrazines | 1 | 2012 | 73 | 0.090 |
Why?
|
| Treatment Outcome | 11 | 2015 | 13114 | 0.090 |
Why?
|
| Hypnotics and Sedatives | 1 | 2012 | 138 | 0.090 |
Why?
|
| Lipocalins | 1 | 2011 | 30 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2012 | 5455 | 0.090 |
Why?
|
| Acute-Phase Proteins | 1 | 2011 | 50 | 0.090 |
Why?
|
| Myocarditis | 1 | 2012 | 133 | 0.090 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2012 | 258 | 0.090 |
Why?
|
| Catheters | 1 | 2011 | 89 | 0.090 |
Why?
|
| DNA, Viral | 1 | 2012 | 497 | 0.090 |
Why?
|
| Ductus Arteriosus | 1 | 2011 | 61 | 0.090 |
Why?
|
| Cystatin C | 1 | 2011 | 66 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2011 | 153 | 0.090 |
Why?
|
| Heparin | 2 | 2008 | 230 | 0.080 |
Why?
|
| Logistic Models | 2 | 2012 | 1902 | 0.080 |
Why?
|
| Echocardiography, Doppler | 1 | 2010 | 173 | 0.080 |
Why?
|
| Catheterization | 1 | 2011 | 239 | 0.080 |
Why?
|
| Norwood Procedures | 1 | 2010 | 105 | 0.080 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 206 | 0.080 |
Why?
|
| Biomarkers | 3 | 2017 | 3422 | 0.080 |
Why?
|
| Pipecolic Acids | 1 | 2008 | 8 | 0.070 |
Why?
|
| Cardiac Catheterization | 2 | 2010 | 669 | 0.070 |
Why?
|
| Oxygen | 1 | 2012 | 578 | 0.070 |
Why?
|
| Drug-Eluting Stents | 1 | 2008 | 70 | 0.070 |
Why?
|
| Transplantation | 1 | 2008 | 27 | 0.070 |
Why?
|
| Heart Septum | 1 | 2008 | 55 | 0.070 |
Why?
|
| Fontan Procedure | 1 | 2010 | 191 | 0.070 |
Why?
|
| Tricuspid Valve | 1 | 2008 | 62 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 40 | 0.070 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2008 | 184 | 0.070 |
Why?
|
| Histocompatibility Testing | 1 | 2007 | 111 | 0.070 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2010 | 272 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 625 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2009 | 211 | 0.070 |
Why?
|
| Angiography | 1 | 2007 | 215 | 0.070 |
Why?
|
| Anticoagulants | 2 | 2008 | 628 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2008 | 237 | 0.060 |
Why?
|
| Body Weight | 1 | 2010 | 1037 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2007 | 310 | 0.060 |
Why?
|
| Cardiology | 1 | 2011 | 521 | 0.060 |
Why?
|
| Oximetry | 1 | 2007 | 178 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2008 | 663 | 0.060 |
Why?
|
| Echocardiography | 1 | 2011 | 1127 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2008 | 685 | 0.060 |
Why?
|
| Kidney | 1 | 2011 | 1395 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 1160 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2007 | 481 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 1 | 2007 | 474 | 0.050 |
Why?
|
| Palliative Care | 2 | 2020 | 466 | 0.050 |
Why?
|
| Hospitals, Pediatric | 1 | 2006 | 795 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2014 | 3644 | 0.040 |
Why?
|
| Terminally Ill | 1 | 2020 | 29 | 0.040 |
Why?
|
| Prevalence | 1 | 2007 | 2639 | 0.040 |
Why?
|
| Reoperation | 2 | 2014 | 853 | 0.040 |
Why?
|
| Graft Survival | 2 | 2012 | 482 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2016 | 1593 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2010 | 2303 | 0.030 |
Why?
|
| Warfarin | 2 | 2008 | 134 | 0.030 |
Why?
|
| Child Welfare | 2 | 2008 | 67 | 0.030 |
Why?
|
| Young Adult | 1 | 2009 | 9926 | 0.030 |
Why?
|
| Critical Care | 1 | 2020 | 698 | 0.030 |
Why?
|
| Sternotomy | 1 | 2014 | 43 | 0.030 |
Why?
|
| Length of Stay | 2 | 2010 | 1392 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 2014 | 110 | 0.030 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2015 | 182 | 0.020 |
Why?
|
| Coronary Circulation | 1 | 2013 | 206 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2010 | 6602 | 0.020 |
Why?
|
| Age Factors | 2 | 2010 | 2987 | 0.020 |
Why?
|
| Bortezomib | 1 | 2012 | 71 | 0.020 |
Why?
|
| Morbidity | 1 | 2012 | 255 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 450 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 1244 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2011 | 76 | 0.020 |
Why?
|
| Lipocalin-2 | 1 | 2011 | 32 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 376 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 603 | 0.020 |
Why?
|
| Pulmonary Valve | 1 | 2012 | 96 | 0.020 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2010 | 15 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2010 | 52 | 0.020 |
Why?
|
| Ventricular Pressure | 1 | 2010 | 39 | 0.020 |
Why?
|
| Tetralogy of Fallot | 1 | 2012 | 166 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2010 | 113 | 0.020 |
Why?
|
| Ventricular Function, Right | 1 | 2010 | 122 | 0.020 |
Why?
|
| Organ Transplantation | 1 | 2012 | 183 | 0.020 |
Why?
|
| Heparin Antagonists | 1 | 2008 | 5 | 0.020 |
Why?
|
| Protamines | 1 | 2008 | 13 | 0.020 |
Why?
|
| Dipyridamole | 1 | 2008 | 22 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 613 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 1616 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2008 | 26 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 1041 | 0.020 |
Why?
|
| Antithrombin III | 1 | 2008 | 28 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2008 | 45 | 0.020 |
Why?
|
| Mitral Valve | 1 | 2010 | 270 | 0.020 |
Why?
|
| Thrombin | 1 | 2008 | 62 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 463 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 543 | 0.020 |
Why?
|
| North America | 1 | 2008 | 266 | 0.020 |
Why?
|
| Energy Intake | 1 | 2010 | 517 | 0.020 |
Why?
|
| Patient Safety | 1 | 2012 | 436 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2008 | 260 | 0.020 |
Why?
|
| Heart | 1 | 2012 | 712 | 0.020 |
Why?
|
| Myocardium | 1 | 2012 | 924 | 0.020 |
Why?
|
| Biopsy | 1 | 2010 | 1204 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 2216 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 569 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2012 | 996 | 0.020 |
Why?
|
| Aspirin | 1 | 2008 | 231 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2008 | 289 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2008 | 311 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2008 | 485 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2008 | 292 | 0.020 |
Why?
|
| Arginine | 1 | 2008 | 350 | 0.020 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2007 | 152 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2007 | 338 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2008 | 478 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2007 | 1145 | 0.010 |
Why?
|
| Texas | 1 | 2012 | 3720 | 0.010 |
Why?
|
| Infant Welfare | 1 | 2003 | 28 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 5219 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 906 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2008 | 998 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2012 | 1124 | 0.010 |
Why?
|
| Adult | 3 | 2012 | 31823 | 0.010 |
Why?
|
| Prognosis | 1 | 2012 | 5071 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2003 | 789 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 2003 | 510 | 0.010 |
Why?
|
| Aged | 1 | 2012 | 21714 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2003 | 3172 | 0.010 |
Why?
|